

Manufacturer	Go live date	Can CE get 340B pricing if they share claims data?	ESP Restoration Logic	Attestation Available?	ESP Day Restrictions	Are system owned contract pharmacies exempted from this policy?	Can CEs with no in-house pharmacy designate a contract pharmacy for 340B pricing access?	Drugs affected by this policy	Policy applies to what entity types?	Important FAQs/Information	Any other Exceptions?
Abbvie	2/1/2022 4/17/23 (New Policy)	Yes but only applies to CEs with no in-house pharmacy. Only one CP designation is allowed and the CP needs to be within 40 miles of the parent site. Such CEs can also designate a second CP for AbbVie's 2 LDDs (Duopa and Imbruvica). No CP access for CEs with in-house pharmacy.	Chain		45 Days	No	Yes but only one CP designation is allowed and the CP needs to be within 40 miles of the parent site. Such CEs can also designate a second CP for AbbVie's 2 LDDs (Duopa and Imbruvica).	CREN®; DEPAKOTE®, DUOPA®, GENGRAF®, HUMIRA®, IMBRUVICA®, KALETRA®, K-TAB®, LUPRON®, MAVYRET®, NIASPAN®, NIMBLEX®, NORVIR®, ORIAHNN®, ORLISSA®, RINVOQ®, SKYRIZI®, SURVANTA®, SYNTHROID®, TRICOR®, TRILIPIX®, ULTANE®, VIEKIRA PAK®, ZEMPLAR®, ACTONEL®, ACULAR®, ACULAR® LS, ACUVAIR®, ALDORIL®, ALPHAGAN® P, ANDRODERM®, ANIMOLUR® THYROID, ASACOL® HD, ATELVAR®, AVICIZ®, BENTYL®, BOTOX®, BUSTOLIC®, CANISA®, CARAFATE®, CELEXA®, COMBIGAN®, CONDYLOX®, CRONON®, DALVANCE®, DELZICOL®, DURYSTA®, ESTRACE®, FETZIMA®, FML®, FML FORTE®, GELNIQUE®, GENERESS® FE, INFED®, KADIAM®, KYBELLA®, LASTACAPT®, LATISSE®, LEXAPRO®, LINZESS®, LO LOESTRIN® FE, LUMIGAN®, MINASTRIN® 24 FE, MONJURO®, NAMENDA® / NAMENDA XR®, NAMZARIC®, OCUFLOX®, OXYNOL®, OXYDEX®, POLYTRIM®, PRED FORTE®, PRED MILD®, PYLERA®, QULIPTA®, RAPAFLO®, RECTIV®, REFRESH®, RESTASIS®, SAPHRIS®, SAVELLA®, TAYTULLA®, TEFLARO®, UBRELVY®, URSO FORTE® / URSO 250®, VANIQA®, VIBERZI®, VIIBRYO®, VRAHLAR®, VLUITY®, ZYMAXID®	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.	Q: If I designate one contract pharmacy location to receive orders of medicines subject to this policy, should I also make a separate designation for a contract pharmacy location to receive AbbVie medicines subject to a limited distribution network? Yes, you should separately designate one contract pharmacy location to receive medicines subject to a limited distribution network. AbbVie will facilitate bill to/ship to orders to this designated pharmacy. Currently, this separate contract pharmacy designation is available for Duopa and Imbruvica. Accordingly, this pharmacy designation may be in addition to the one permitted contract pharmacy designation for other AbbVie medicines. Please access 340B ESP™ at www.340BESP.com to make this selection.	
Amgen	1/3/2022 4/11/23 (New Policy)	Yes - 340B ESP Effective 4/11/23: - Only one contract pharmacy will be allowed to get 340B pricing. - CP will need to be within 40 miles of the main CE - If the CE has in-house pharmacies then CE will be required to share data for all in-house pharmacies in order to get 340B pricing for one CP.	Chain		45 Days	Yes but cannot designate "an independent contract pharmacy" outside of that.	Yes (CP will need to be within 40 mile radius of the CE). Data sharing with ESP will be required.	Policy currently applies to only Repatha, Enbrel, Otezla, Aimovig, Tezpire and Amjevta. Policy does not apply to any medical benefit products	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.		
Astellis	9/1/23	Yes - 340B ESP				Yes but cannot designate "an independent contract pharmacy" outside of that.	Yes	Policy currently applies to Xtandi	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.		
AstraZeneca	10/1/2020 8/1/2023 (New Policy)	No			45 Days	No	Yes	All products except Tagrisso and Calquence	All covered entity types except for Ryan White, Community Health Centers and Federal Grantees		
Bausch Health	8/1/2022 6/26/23 (New Policy)	Yes - 340B ESP	Store by store basis	Yes	45 Days	Yes but cannot designate "an independent contract pharmacy" outside of that.	Yes (CP will need to be within 40 mile radius of the CE)	All Products (no exceptions)	All covered entity types (no exceptions)		
Bayer	3/1/2023 6/1/23 (New Policy)	No (data sharing is voluntary)			45 Days	No	Yes (CEs with no in-house pharmacies can select one additional CP for Adempas. The non Adempas CP has to be within 40 miles of the CE. No mileage restriction for Adempas CP. CEs with in-house pharmacies are allowed to designate one CP for Adempas.	All products except Aliqopa, Jivi, Kerendia, Kogenate, Kovaltry, Kyleena, Lampit, Mirena, Skyia, Nubeqa, Xofigo	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.		
Biogen	2/1/23	No				Yes	Yes	Only 2 products- Avonex and Plegridy	Only Hospital CEs (Federal grantees are exempted from this policy)		
Boehringer Ingelheim	8/1/21	No				Yes (reach out to support@340bsep.com to apply for the exemption)	Yes; policy also states that if a CE has an in-house pharmacy that is NOT capable of dispensing specialty products, then CE may designate one specialty pharmacy from within BI's limited distribution network for the sole purpose of dispensing OFEV to its patients.	All products except Giltarif and Praobind	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.		
Bristol Myers Squibb	3/1/22	Yes but conditions apply: - Applies only to IMiDs (Revlimid, Pomalyst and Thalomid) - Wholesaler has to be ABC - CE cannot already be part of BMS network through their in-house pharmacy for the IMiDs - If all conditions are met then CE can designate one BMS approved specialty pharmacy. BMS will then provide a claims submission template to the entity. The CE should email the completed template to BMSCEgen@340BSP@web.bms.com. See link below for the complete list of SPs approved to dispense these IMiDs: https://www.bms.com/patient-and-caregivers/risk-evaluation-and-migration-strategies/rem.html	N/A		60 days	Yes	Yes (CEs can designate 2 CPs - one for non-IMiD products and one for IMiD products) but certain conditions apply: - Applies only to IMiDs (Revlimid, Pomalyst and Thalomid) - Wholesaler has to be ABC - If both conditions are met then CE can designate one BMS approved specialty pharmacy. See the link below for the complete list of SPs approved to dispense these IMiDs: https://www.bms.com/patient-and-caregivers/risk-evaluation-and-migration-strategies/rem.html	All Products (no exceptions)	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.		
Esai	11/1/23	Yes - 340B ESP	NA	NA	NA	No	Yes	ARICEPT®, BANZEL®, DAYVIGO®, HALAVEN®, LENVIMA®, and LEGEMBI™	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.	pharmacy options may be available pursuant to Arkansas and Louisiana state law.	
EMD Serono	3/1/2023 10/1/23 (New Policy)	No	NA	NA	NA	Yes	Yes	All Products (no exceptions)	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.	pharmacy options may be available pursuant to Arkansas and Louisiana state law.	
Exelixis	7/6/2022 6/26/23 (New Policy)	Yes - 340B ESP	Chain		None Noted	Yes but data sharing is required (effective 6/26/23)	Yes (1 Contract Pharmacy Location within Specialty Network)	CABOMETYX®, COMETRIQ®	All covered entity types (no exceptions)		
Gilead	5/2/22	Yes - 340B ESP	Chain	Yes	45 Days	Yes	Yes	EPCLUSIA, HARVONI, SOVALDI and VOSEVI	All covered entity types (no exceptions)		
GSK	4/1/2022 5/1/23 (New Policy)	No	Chain	Yes	45 Days	Yes	Yes (one CP and no mileage restriction)	All GSK products, OJJARA added on 10/3/2023	All covered entity types (no exceptions)		
Incyte	10/16/23	No				No	Yes (within 40 miles)	OPZELURA®	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.		

Jazz	10/9/23	No				No	Yes	Epidiolex Only	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.	
Johnson and Johnson	5/2/2022 3/7/23 (New Policy)	Yes - 340B ESP but conditions apply (see below) Effective 3/7/23 (for Non-PAH Drugs) - Only one contract pharmacy will be allowed to get 340B pricing. - CP will need to be within 40 miles of the main CE - If the CE has in-house pharmacies then CE will be required to share data for all in-house pharmacies in order to get 340B pricing for one CP. Effective 3/7/23 (for PAH drugs) - Only one CP designation allowed. No 40 mile radius requirement since only Accredited pharmacies are eligible to receive 340B replenishments for PAH drugs. - No in-house pharmacy data sharing required.	Chain	Yes	45 Days	No (effective 3/7/23)	Only one CP designation allowed regardless of whether the CE has in-house pharmacies or not	STELARA®, TREMFYA®, SIMPONI ARIA®, SIMPONI®, REMICADE®, XARELTO®, INVOKAMET®, INVOKAMET® XR, INVOKANA®, DARZALEX®, DARZALEX FASPRO®, ERLEADA®, INVEGA HAFYERA®, INVEGA SUSTENNA®, INVEGA TRINZA®, INVEGA®, OPSUMIT®, UPRAVI®, TRACLEER®, VELETRI®, SYMTUZA®, PREZCOBIX®, EDURANT®, ELMIRON®, TOPAMAX®, YONDELIS®, RYBREVANT®, PREZISTA®, ZYTIGA®, PROCRI®, EDURANT®, ELMIRON®, TOPAMAX®, YONDELIS®	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.	
Lilly	7/1/20 (CIALIS), 9/1/20 (ALL NDCs)	Yes - 340B ESP	Store by store basis		45 Days	Yes	Yes	All Products (no exceptions)	All covered entity types (no exceptions)	For hospitals that register and provide data for Lilly's NDCs via ESP on or before Mar. 15, 2022, Lilly will honor contract pharmacy replenishment purchases for prescriptions dispensed to eligible 340B patients on or after Oct. 29, 2021. Replenishment orders for prescriptions dispensed prior to Oct. 29, 2021 will not be honored. Starting on Mar. 15, 2022, all contract pharmacy replenishment orders for all hospitals registered with ESP will be honored for prescriptions dispensed to eligible 340B patients within 45 days of each data submission to ESP. Certain insulin products are exempted from this policy but certain conditions apply: - Point of sale price has to be equal to the 340B price - No mark up fees of any kind can be charged to the patient - No insurer or payor can be billed (this exception only applies if the CE doesn't decide to share data through 340B ESP). If CE is sharing the data then no conditions apply for insulin products
Merck	9/1/2021 6/12/23 (New Policy)	No	One Claim Restores All		45 Days	No	Yes (within 40 miles)	BELSOMRA JANUVIA, JANUMET, JANUMET XR, STEGLATRO, STEGLUJAN, SEGLUROMET, and VERQUIVO.	All covered entity types except for Grantees	
Novartis	10/1/2020 5/1/23 (New Policy)	No				Yes	Yes (no mileage restriction)	All Products (no exceptions)	All covered entity types except for Grantees	This exception only applies to contract pharmacies that are more than 40 miles away from the parent location. Any contract pharmacies within 40 miles of the parent location can have unlimited access to Novartis products. New Policy (5/3/23): 40 mile radius rule does not apply any more. No CP access for Novartis products if the CE has in-house pharmacy. CEs with no in-house pharmacy can designate one external CP (no mileage restriction)
Novo Nordisk	3/1/2021 7/1/23 (New Policy)	Yes but only limited to a max of 2 CP designations (one retail/one specialty) for all hospital CEs			45 Days	No (CEs can designate as many wholly owned pharmacies but data sharing is required)	2 CP designations apply to CEs with or without in-house pharmacies	All Products (no exceptions)	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.	
Organon	7/1/23	Yes but only one CP for all applicable CEs (regardless of whether the CE has an in-house pharmacy or not)				No	Yes but policy applies equally for all applicable CEs (with or without in-house pharmacies)	All Products (no exceptions)	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.	
Pfizer	3/1/2022 5/1/23 (New Policy: Only applies to Xeljanz) 11/1/23 (New Policy: Only applies to Vyndamax and Vyndaqel)	Yes but only for Pfizer's Defined Oncology Distribution Network (DON) Effective 5/1/23: No 340B pricing for Xeljanz specifically for CEs with in-house pharmacy Effective 11/1/23: 340B pricing only available for Vyndamax and Vyndaqel if claims data is shared with 340B ESP	Store by store basis		45 Days	No (effective 4/30/23- only applies to Xeljanz) Wholly owned allowed 340B pricing for Vyndamax and Vyndaqel as long as the CEs are under VVND A network.	Yes (CEs can designate 2 CPs - one for Xeljanz specifically and a specialty pharmacy for other oral oncology products affected by this policy. CEs can designate one VVND A network specialty CP for Vyndamax and Vyndaqel as well.	Xeljanz, Bosulfil, Braftovi, Daurismo, Ibrance, Inlyta, Lorbrina, Mektovi, Sutent, Talazena, Xalkori, Vyndamax and Vyndaqel. Effective 5/1/23 (for Xeljanz) and 11/1/23 (for drug list outlined in Exhibit A of 10/2/23 Notice), no CP access for CEs with in-house pharmacies.	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.	
Sanofi	10/1/2020 6/1/23 (New Policy)	No	One Claim Restores All	Yes	45 Days	No	Yes (no mileage restriction)	Adlyxin™ Admelog™ Amaryl™ Ambien™ Apidra™ Arava™ Availed™ Avapro™ Doxercalciferol™ Dupixent Enoxaparin Sodium™ Flomax™ Insulin Glargine™ Ibesartan™ Kezara™ Lantus™ Leflunomide™ LovenoX™ Multaq™ Plavix™ Pritin™ Primaquin™ Renegel™ Renvel™ Sevelamer™ Soliqua™ Toujeo™ Zolpidem™	New policy applies to CAPs, DSH, RRCs and SCIs only. Consolidated Health centers can get access to unlimited number of contract pharmacies if they share data with ESP. Federal grantees are exempted from this policy.	
Teva	7/5/23	No				No	Yes	All Products (no exceptions)	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.	
UCB	12/13/2021 10/2/23 (New Policy)	No				No	Yes but the pharmacy needs to be located within 40 miles of the CE parent site.	All Products (no exceptions)	Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.	
United Therapeutics	12/1/21	Yes but CEs also need to have a valid 340B purchase of one of the company's covered outpatient drugs from the contract pharmacy during the first 3 quarters of 2020. If no purchases in the first 3 quarters of 2020 then no 340B pricing is offered even if the CE shares the data through 340B ESP.			45 Days	No	Yes	All Products except Adcirca	All covered entity types (no exceptions)	